1. Pink Sheet
  2. >>Market Access

Driving Rx Adherence In Value-Based Insurance Design Needs More Than Lower Copays – Harvard Researcher

 
• By Gregory Twachtman

Value-based insurance design offers the promise of offering better quality care and helping to reduce costs, but getting there will require more than trying to influence behavior by reducing copayments, Harvard’s Choudhry said in a recent webinar.

Promoting changes in copayments/co-insurance that are beneficial to patients will not be enough to drive patients to use the most effective drugs in value-based insurance designs, Harvard’s Niteesh Choudhry said during a recent webinar.

Speaking during the Feb. 27 World Congress-sponsored webinar, “Scaling Patient Outcomes Through Leveraging Value Based Insurance Design Principles,” Choudhry opened...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Global Guideline Signals ‘Paradigm Shift’ For Pregnant And Breastfeeding Women, Says EMA

 
• By Anabel Costa-Ferreira

The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges